Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656238 | 1.00 | HTR7 (0.53) | HTR7ENPP2DRD2DRD3DRD4 | |
| SCHEMBL5657837 | 0.87 | HTR1A (0.56) | HTR7DRD2DRD4ALDH1A1HTR1A | |
| SCHEMBL5657971 | 0.86 | KCNH2 (0.50) | HTR7DRD2DRD3DRD4ALDH1A1 | |
| SCHEMBL5657779 | 0.86 | HTR1A (0.59) | HTR7MEN1KMT2AHTR1ASIGMAR1 | |
| SCHEMBL5656134 | 0.86 | HTR1A (0.48) | HTR7DRD4HTR1ALMNAMAPT | |
| SCHEMBL5656201 | 0.85 | HTR1A (0.55) | HTR7DRD2DRD3DRD4MEN1 | |
| SCHEMBL5654667 | 0.82 | HTR7 (0.53) | HTR7HTR1ASIGMAR1MAPT | |
| SCHEMBL5655950 | 0.81 | HTR1A (0.50) | HTR7DRD4HTR1ASIGMAR1MAPT | |
| SCHEMBL5658017 | 0.81 | HTR7 (0.58) | HTR7DRD2DRD4MEN1KMT2A | |
| SCHEMBL5656018 | 0.81 | KCNH2 (0.54) | HTR7DRD2DRD3DRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | CEREP (FR) | 2005-12-01 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | HTR7 13/4885ENPP2 636/4885DRD2 73/4885 |
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | HTR4, HTR2B, HTR1B | HTR7 9/4885ENPP2 504/4885DRD2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.